Education
About Us
Working with TipRanks
Follow Us
TScan Therapeutics (TCRX)
NASDAQ:TCRX
TCRX Stock Chart & Stats
$1.01
-$0.17(-5.65%)
At close: 4:00 PM EST
$1.01
-$0.17(-5.65%)
Day’s Range― - ―
52-Week Range$0.88 - $2.57
Previous CloseN/A
Volume150.47K
Average Volume (3M)461.27K
Market Cap
$57.88M
Enterprise Value-$16.57M
Total Cash (Recent Filing)$184.45M
Total Debt (Recent Filing)$95.62M
Price to Earnings (P/E)―
Beta2.04
Next Earnings
Mar 11, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding52,471,405
10 Day Avg. Volume410,026
30 Day Avg. Volume461,267
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.41
Price to Sales (P/S)120.90
P/FCF Ratio-2.97
Enterprise Value/Market Cap-0.29
Enterprise Value/Revenue-1.97
Enterprise Value/Gross Profit-2.16
Enterprise Value/Ebitda0.12
Forecast
1Y Price Target
$6.50Price Target Upside543.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 1 ALLOHA updates showing a substantially lower relapse rate for TSC-101–treated patients versus control, along with favorable relapse-free and overall survival trends, strengthen the product’s clinical value proposition.
Manufacturing And Commercial ReadinessAdoption of a 12-day commercial-ready manufacturing process that reduces ex vivo expansion and cost of goods, with early runs indicating robust cell yield, supports scalability for higher dosing and potential retreatment strategies.
Regulatory ClarityFDA alignment on the pivotal trial design and a targeted start in 2Q26 clarify regulatory expectations and materially reduce execution risk for TSC-101's registration path.
Bears Say
Catalyst And Valuation RiskAbsence of identifiable near-term catalysts combined with conservative financial modeling increases the risk that valuation may not reflect meaningful upside before pivotal readouts.
Efficacy Variability At Higher DosesEmergence of disease recurrence, with particular shortfalls among patients treated at the highest dose, raises concerns about dose optimization and consistent clinical benefit across cohorts.
Program Concentration And Pipeline RiskPause of the PLEXI-T solid tumor study and deprioritization of TCR-Ts in solid malignancies narrow the pipeline and concentrate clinical and commercial risk on the heme program.
TScan Therapeutics News
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $0.88 and its highest was $2.57 in the past 12 months.
What is TScan Therapeutics’s market cap?
TScan Therapeutics’s market cap is $57.88M.
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Mar 11, 2026 which is in 16 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.334 by $0.054.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 52,471,405 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.334. Following the earnings report the stock price went down -2.459%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Currently, no hedge funds are holding shares in TCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (543.56% Upside)
$6.50 (543.56% Upside)
Blogger Sentiment
Bullish
TCRX Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $144.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 9.5%
Last 30 Days ▼ 9.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.88%
12-Months-Change
Fundamentals
Return on Equity
-76.44%
Trailing 12-Months
Asset Growth
-24.65%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TCRX Stock 12 Month Forecast
Average Price Target
$6.50
▲(543.56% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
ALX Oncology Holdings
―
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
Ownership Overview
20.34% Insiders
5.92% Mutual Funds
2.12% Other Institutional Investors
67.41% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---